A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes

NCT04956263 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 1
Type1diabetes
Diabetes Mellitus

Interventions

DRUG: YG1699
DRUG: Dapagliflozin

Sponsor

Youngene Therapeutics Inc., Ltd.

Collaborators

[object Object]